Cutia Therapeutics
2487.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$312.5M
Close$
Share Statistics
| Market cap | $312.50 Million |
|---|---|
| Enterprise Value | $434.73 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.03 |
| Beta | 0.45 |
| Outstanding Shares | 363,368,277 |
Return
| Return on Equity | -105.93% |
|---|---|
| Return on Assets | -70.18% |
| Return on Invested Capital | -83.19% |
Valuation & Multiples
| P/E Ratio | -0.93 |
|---|---|
| PEG | 3.77 |
| Price to Sales | 0.74 |
| Price to Book Ratio | 0.74 |
| Enterprise Value to Revenue | 0.75 |
| Enterprise Value to EBIT | -0.61 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.63 |
| Debt to Equity | 0.39 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$72.51 M
Average shareholder expectationNext Earnings Call
Expected Date
March 30, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$97.30 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cutia Therapeutics
268 employees
CEO: Lele Zhang Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological ch...